Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 31-September 5, 2025: 1. Mitapivat PDUFA for Thalassemia Delayed to December  The FDA extended the review timeline for mitapivat in thalassemia, with a new decision date set for December 2025. 2. Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years Arcutis submitted an sNDA seeking to expand roflumilast cream’s indication to include plaque psoriasis in children as young as 2. 3. Zilebesiran, RNAi for Hypertension, Heads to Phase 3 Cardiovascular Outcomes Trial Alnylam is advancing zilebesiran into a phase 3 outcomes trial to evaluate its impact on cardiovascular risk in patients with uncontrolled hypertension. 4. RestorAATion-2: WVE-006 Achieves Durable Serum AAT Protein Production in AATD Wave Life Sciences reported durable serum AAT protein production with WVE-006 in AATD, supporting its potential for disease modification. 5. Phase 3 Data Show Amlitelimab Effective in Adults, Adolescents with Atopic Dermatitis Sanofi announced phase 3 results showing amlitelimab improved disease severity and skin clearance in moderate-to-severe atopic dermatitis.